Abstract:Introduction: Targeting innate immune checkpoints on tumor-associated macrophages (TAMs) like CD40 activation or CD47 blockade is currently tested as a promising new therapeutic strategy in pancreas cancer. The mannose receptor CD206 is expressed on M2-like TAM populations and activation of CD206 can recalibrate these immune suppressive cells towards an anti-tumor M1-like phenotype to elicit effective innate immune responses and tumor control. The lack of a detailed understanding of the molecular mechanisms of CD206-mediated macrophage reprogramming, however, is an impediment for the design of novel, effective combination studies or the development of accurate biomarkers. Methods: Single-cell RNA-Seq analysis of TAM populations of autochthonous KP16 and KPC tumors treated with a CD206 checkpoint modulator was used to classify CD206 positive M2-like TAMs into responsive vs non-responsive to CD206 modulation. Candidates of differentially expressed innate immune regulators were evaluated for their role in CD206 activation in macrophages derived from transgenic knockout mouse models deficient for different innate immune regulators. The induction of CD206 protein-protein interactions with other innate immune regulators was examined via proximal ligation assays (PLA) or co-immunoprecipitation, as well as a series of CD206 mutants expressed in different reporter assays. CCR2-RFP transgenic mice were used to study cancer cell phagocytosis in vitro and in vivo. Results: CD206 activation via small molecule candidate NCGC00413972 induces a conformational change in CD206 which induces the formation of a TLR1/2-CD206 trimeric complex, activates SYK kinase, recruits MyD88, and activates NF-κB and type I interferon signaling. Carbohydrate recognition domain 3 (CRD3) of the non-activated CD206 receptor negatively regulates CD206-TLR1/2 interaction. CD206 small molecule ligation, or the deletion of the N-terminal CRDs of CD206, leads to the formation of active TLR1/2-CD206 complexes, NF-κB activation, and TAM reprogramming. Loss of SYK kinase binding sites in the cytoplasmatic domain of CD206 or inhibition of SYK abrogates NF-κB activation and reduces cell death of M2-like macrophages but does not affect interferon signaling or cancer cell phagocytosis. The combination of an FDA-approved SYK inhibitor with a CD206 small molecule activator increased the fraction of M2-to-M1 reprogrammed TAMs and cancer cell phagocytosis in the tumoral stroma of KPC mice. CD206 and TLR2 activators also cooperated in the reprogramming of TAMs, resulting in a recalibration of the immune landscape towards an anti-tumor phenotype and enhanced tumor control. Conclusions: Deconvolution of the mechanism of action of CD206 small molecule activation identifies toll-like receptor signaling as an essential co-regulator for the induction of innate immune responses. Co-stimulation of CD206 and TLR2 demonstrates therapeutic potential as an effective immunotherapy in a recalcitrant disease, as it cooperatively increases NF-κB signaling, cancer cell phagocytosis, and recalibrates myeloid cells. Citation Format: Sitanshu Sekhar Singh, Rushikesh V. Sable, Anju Kumari, Xin Hu, Abhijeet Kapoor, Raul Calvo, Emily Major, Taivan Odzorig, Laura Bassel, Serguei Kozolov, Mark Henderson, Juan Marugan, Udo Rudloff. CD206 small molecule activation recruits TLR1/2 to enhance cancer cell phagocytosis in reprogrammed tumor-associated macrophages and improves tumor control [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer; 2022 Sep 13-16; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2022;82(22 Suppl) nr C024.

Fatty acid derivatization and cyclization of the immunomodulatory peptide RP-182 targeting CD206high macrophages improves anti-tumor activity

Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses

Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy

Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy

Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype

Targeting tumor-associated macrophages with mannosylated nanotherapeutics delivering TLR7/8 agonist enhances cancer immunotherapy

Abstract C024: CD206 small molecule activation recruits TLR1/2 to enhance cancer cell phagocytosis in reprogrammed tumor-associated macrophages and improves tumor control

Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy

Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy

Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration

Regulating Tumor-Associated Macrophage Polarization by Cyclodextrin-Modified PLGA Nanoparticles Loaded with R848 for Treating Colon Cancer

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy

Dual-Targeting of Tumor Cells and Tumor-Associated Macrophages by Palmitic Acid Modified Albumin Nanoparticles for Antitumor and Antimetastasis Therapy

Supramolecular Peptide Amphiphile Nanospheres Reprogram Tumor‐associated Macrophage to Reshape the Immune Microenvironment for Enhanced Breast Cancer Immunotherapy

A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy

Abstract 2964: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042

In Situ Reprogramming of Tumor-Associated Macrophages Enhances Cancer Immunotherapy

An in-situ peptide-antibody self-assembly to block CD47 and CD24 signaling enhances macrophage-mediated phagocytosis and anti-tumor immune responses

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials

Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors

In situ repolarization of Tumor-Associated Macrophages with synergic nanoformulation to reverse immunosuppressive TME in mouse breast cancer for cancer therapy